Skip to main content

Table 6 Haplotype distribution in patients and controls and association with breast cancer risk

From: Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study

   Cases Controls    
  Haplotype N F N F OR 95%CI P χ2
  AAGT 284 0.47 248 0.47 1   
1 AAG C 72 0.12 63 0.12 0.99 0.68-1.45 0.92
  G A CC 60 0.1 48 0.09 1.09 0.72-1.62 0.68
  AA CC 54 0.09 42 0.08 1.12 0.72-1.73 0.65
  G AG C 6 0.01 0 0    0.03*
  Total 192 0.32 153 0.29 1.09 0.83-1.43 0.5
2 A G GT 66 0.11 53 0.1 1.08 0.72-1.62 0.68
  AA C T 30 0.05 26 0.05 1.00 0.58-1.75 1
  G A C T 24 0.04 26 0.05 0.80 0.45-1.44 0.46
  A GC T 0 0 5 0.01    0.02*
  G AGT 0 0 5 0.01    0.02*
  Others 8 0.01 12 0.02 0.58 0.23-1.44 0.23
  Total 128 0.21 127 0.24 0.88 0.65-1.18 0.4
  Total 604 1 528 1    
  1. The haplotype combining the predominant alleles was used as a reference. Group 1 was formed by any haplotype containing the rs5275 C allele and group 2 included all the other haplotypes. The haplotypes with less than 1% frequency (Others) are not listed. The impact on breast cancer risk was calculated for the two groups, considering the Odds Ratio (OR) and the 95% Confidence Interval (95%CI) P: Pearson P-value; N: Number of haplotypes. F: Frequency of haplotypes. * Fisher Exact Probability Test (two-tailed). OR was not calculated because of N = 0.